Examining the Proposed Biological Definition of Neuronal Alpha-Synuclein Disease and Staging System with Lana Chahine

For many years, Parkinson's disease and dementia with Lewy bodies have been defined using clinical features. With recent advances in biomarkers, particularly the alpha-synuclein seed amplification assay that allows us to detect misfolded and aggregated alpha-synuclein in cerebrospinal fluid, it is now possible to identify the presence of pathological neuronal alpha-synuclein in living patients. With input from diverse stakeholders, a new biological definition of neuronal alpha-synuclein disease (NSD) has been proposed, along with an integrated staging system (NSD-ISS). In this interview, we discuss the development of this biologic definition for Parkinson’s disease and the staging system with Dr. Lana Chanine, one of the lead authors of the recently published manuscript in The Lancet Neurology that describes this work. It is important to note that the NSD and NSD-ISS are for research purposes only right now, and they are not ready to be implemented in the clinic. Lana is a Movement Disorders Neurologist and Associate Professor of Neurology at the University of Pittsburgh.Mentioned in this episode:August is Make-A-Will Month, which serves as a reminder of the importance of creating and updating your will. Use this moment to take control of your future and ensure your wishes are respected. Visit michaeljfox.org/plan to learn more and get started.This podcast episode was part of a limited series created by The Michael J. Fox Foundation in 2023 and 2024 for clinicians and researchers in our audience.  These episodes provide a deeper dive into exciting new scientific research in Parkinson’s disease, as well as innovative tools and valuable resources, through conversations with a variety of experts in the field. We hope you enjoy the conversation.